Posted by Michael Wonder on 19 Apr 2017
NICE nod for Novartis’ Cosentyx in psoriatic arthritis
19 April 2017 - NICE has published a positive Final Appraisal Determination which backs NHS use of Novartis’ Cosentyx (secukinumab) in adults with active and progressive psoriatic arthritis.
The cost watchdog is recommending use of Cosentyx (secukinumab) when a patient has peripheral arthritis with three or more tender joints and three or more swollen joints, and has not responded to adequate trials of at least two standard disease-modifying anti-rheumatic drugs, administered either individually or in combination.
